Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Summary

Phase II trial to study the effectiveness of combining zoledronate with BMS-275291 in treating patients who have prostate cancer that has not responded to previous hormone therapy. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone. BMS-275291 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Combining zoledronate with BMS-275291 may kill more tumor cells.

Timeline

Start

2002-04

Primary completion

2005-01

Completion

—

Drugs

Indications